全球mRNA疫苗和治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

mRNA疫苗和治疗市场预计将从2025年的317.4亿美元成长到2034年的1,145亿美元，2026年至2034年的复合年增长率为15.32%。

随着基于mRNA的新冠疫苗成功上市，全球mRNA疫苗和疗法市场经历了快速成长。这项技术展现出快速研发能力、高效性和扩充性，彻底革新了疫苗的研发模式。除了感染疾病，mRNA平台在癌症免疫疗法、罕见遗传疾病和个人化医疗等领域的应用研究也正在进行中。

成长要素包括政府的大量拨款、持续的研发投入以及生物技术领域合作的不断拓展。脂质奈米颗粒递送系统的进步和mRNA稳定性的提高显着改善了临床疗效。该平台具有极强的适应性，能够快速改进以靶向新的病原体，使其成为全球公共卫生策略中极具价值的技术。

随着製药公司不断拓展肿瘤、自体免疫疾病和代谢性疾病领域的研发管线，前景极为乐观。储存、分销和生产流程的持续改进将提升商业性可行性。随着研究不断拓展治疗适应症，mRNA技术可望彻底改变现代医学，并有望实现长期持续的市场成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球mRNA疫苗与治疗市场：以mRNA类型划分

• 市场分析、洞察与预测
• 核苷修饰的mRNA
• 未修饰的mRNA
• 自扩增mRNA

第五章 全球mRNA疫苗与治疗市场：依类型划分

• 市场分析、洞察与预测
• 为了预防
• 治疗药物

第六章 全球mRNA疫苗与治疗市场：依应用划分

• 市场分析、洞察与预测
• 感染疾病
• 肿瘤学
• 罕见遗传疾病
• 其他呼吸系统疾病等。

第七章 全球mRNA疫苗与治疗市场：依最终使用者划分

• 市场分析、洞察与预测
• 医院和诊所
• 生物製药公司
• 其他的

第八章 全球mRNA疫苗与治疗市场：按地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • ModernaInc
  • BioNTech SE
  • CureVac SE
  • Arcturus TherapeuticsInc
  • Sanofi
  • GSK Plc
  • Argos Therapeutics Inc
  • Ethris
  • Pfizer Inc
  • AstraZeneca

The mRNA Vaccine And Therapeutics Market size is expected to reach USD 114.50 Billion in 2034 from USD 31.74 Billion (2025) growing at a CAGR of 15.32% during 2026-2034.

The Global mRNA Vaccine and Therapeutics Market witnessed exponential growth following the successful deployment of mRNA-based COVID-19 vaccines. The technology demonstrated rapid development capabilities, high efficacy, and scalability, transforming vaccine research and production. Beyond infectious diseases, mRNA platforms are being explored for cancer immunotherapy, rare genetic disorders, and personalized medicine applications.

Key growth drivers include substantial government funding, ongoing R&D investments, and expanding biotech partnerships. Advances in lipid nanoparticle delivery systems and improved mRNA stability have strengthened clinical outcomes. The platform's adaptability allows quick modification to target emerging pathogens, making it highly valuable in global public health preparedness strategies.

Future prospects are exceptionally strong as pharmaceutical companies expand pipelines for oncology, autoimmune, and metabolic diseases. Continuous improvements in storage, distribution, and manufacturing processes will enhance commercial viability. As research broadens therapeutic indications, mRNA technology is expected to revolutionize modern medicine, ensuring sustained long-term market growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By mRNA Type

Nucleoside-modified mRNA

Unmodified mRNA

Self-amplifying mRNA

By Type

• Prophylactic
• Therapeutic

By Application

• Infectious Diseases
• Oncology
• Rare Genetic Diseases
• Others (Respiratory Diseases, etc)

By End-user

• Hospitals & Clinics
• Biopharmaceutical Companies
• Others

COMPANIES PROFILED

• Moderna, Inc, BioNTech SE, CureVac SE, Arcturus Therapeutics, Inc, Sanofi, GSK plc, Argos Therapeutics Inc, Ethris, Pfizer Inc, AstraZeneca

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY MRNA TYPE 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Mrna Type
• 4.2. Nucleoside-modified mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Unmodified mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.4. Self-amplifying mRNA Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Type
• 5.2. Prophylactic Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Therapeutic Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.4. Rare Genetic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.5. Others Respiratory Diseases, etc Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY END-USER 2022-2034 (USD MN and Million Doses)

• 7.1. Market Analysis, Insights and Forecast End-user
• 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.3. Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 8. GLOBAL MRNA VACCINE AND THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.2.1 By Mrna Type
  • 8.2.2 By Type
  • 8.2.3 By Application
  • 8.2.4 By End-user
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.3.1 By Mrna Type
  • 8.3.2 By Type
  • 8.3.3 By Application
  • 8.3.4 By End-user
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.4.1 By Mrna Type
  • 8.4.2 By Type
  • 8.4.3 By Application
  • 8.4.4 By End-user
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.5.1 By Mrna Type
  • 8.5.2 By Type
  • 8.5.3 By Application
  • 8.5.4 By End-user
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 8.6.1 By Mrna Type
  • 8.6.2 By Type
  • 8.6.3 By Application
  • 8.6.4 By End-user
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MRNA VACCINE AND THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 ModernaInc
  • 10.2.2 BioNTech SE
  • 10.2.3 CureVac SE
  • 10.2.4 Arcturus TherapeuticsInc
  • 10.2.5 Sanofi
  • 10.2.6 GSK Plc
  • 10.2.7 Argos Therapeutics Inc
  • 10.2.8 Ethris
  • 10.2.9 Pfizer Inc
  • 10.2.10 AstraZeneca